<![CDATA[Genmab — August 2017]]>Efter markedsluk - altså kl 17.00

]]>https://dev.proinvestor.com/forum/topic/451509/genmab-august-2017RSS for NodeSun, 14 Jun 2026 07:04:15 GMTTue, 01 Aug 2017 02:53:50 GMT60<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 16:42:09 GMT]]>Fagre nye ( spændende ) verden. Nordic nanovector er inde på det samme , bare med nano partikler

]]>https://dev.proinvestor.com/forum/post/10156150https://dev.proinvestor.com/forum/post/10156150Thu, 31 Aug 2017 16:42:09 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 16:35:39 GMT]]>http://www.telegraph.co.uk/science/2017/08/30/nanomachines-drill-cancer-cells-killing-just-60-seconds-developed/ Glemte link

]]>https://dev.proinvestor.com/forum/post/10156147https://dev.proinvestor.com/forum/post/10156147Thu, 31 Aug 2017 16:35:39 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 16:34:06 GMT]]>En lille artikel om nanomaskiner i cancerceller, kan dræbe dem på 60 sec. De er så små og kan pakkes så tæt at der kan være 50.000 på diameteren af et hår. Lyder meget spændende og fascinerende, men har desværre nok lange udsigter endnu måske?

]]>https://dev.proinvestor.com/forum/post/10156148https://dev.proinvestor.com/forum/post/10156148Thu, 31 Aug 2017 16:34:06 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:57:31 GMT]]>Husker desværre ikke hvad det var. En lille historie om, hvor effektiv adc teknologien kan være http://www.pvanuden.com/2014/04/antibody-drug-conjugates-adcs-new-type.html

]]>https://dev.proinvestor.com/forum/post/10156145https://dev.proinvestor.com/forum/post/10156145Thu, 31 Aug 2017 15:57:31 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:45:59 GMT]]>hæh. Det er jo nok ikke kemo...

]]>https://dev.proinvestor.com/forum/post/10156151https://dev.proinvestor.com/forum/post/10156151Thu, 31 Aug 2017 15:45:59 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:44:31 GMT]]>Ja mon ikke. Nu har jeg ledt efter nogle prekliniske figurer, hvor en kombipartner viser rigtigt gode figurer. Men det er ikke lykkedes for mig endnu.

]]>https://dev.proinvestor.com/forum/post/10156149https://dev.proinvestor.com/forum/post/10156149Thu, 31 Aug 2017 15:44:31 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:33:57 GMT]]>Kan et adc egentlig indgå i en kombobehandling?

]]>https://dev.proinvestor.com/forum/post/10156140https://dev.proinvestor.com/forum/post/10156140Thu, 31 Aug 2017 15:33:57 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:33:07 GMT]]>TF som target er jo mind boggling ift potentiale

]]>https://dev.proinvestor.com/forum/post/10156142https://dev.proinvestor.com/forum/post/10156142Thu, 31 Aug 2017 15:33:07 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:24:58 GMT]]>Men så får GEN jo bare Actelion premium...

]]>https://dev.proinvestor.com/forum/post/10156144https://dev.proinvestor.com/forum/post/10156144Thu, 31 Aug 2017 15:24:58 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:24:16 GMT]]>Haha. Den er jeg også helt med på - det er måske fordi sgen bliver "US" belønnet og GEN bliver Europa belønnet...

]]>https://dev.proinvestor.com/forum/post/10156143https://dev.proinvestor.com/forum/post/10156143Thu, 31 Aug 2017 15:24:16 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:20:30 GMT]]>http://files.shareholder.com/downloads/AMDA-KPIBN/3691997971x0x668195/DEC9A61F-6B95-41AA-94A0-02FD1DE98107/2013_TF_ASCO_Breij_poster.pdf En tidlig poster på TV, der bl.a. viser hvilke cancerformer, der udtrykker TF. Cervical er ikke den type der udtrykker TF mest ! Så data fra de andre grupper bliver interessante.

]]>https://dev.proinvestor.com/forum/post/10156138https://dev.proinvestor.com/forum/post/10156138Thu, 31 Aug 2017 15:20:30 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:18:20 GMT]]>JV der er da gode nyheder på ESMO for SGEN 😉

]]>https://dev.proinvestor.com/forum/post/10156141https://dev.proinvestor.com/forum/post/10156141Thu, 31 Aug 2017 15:18:20 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:18:08 GMT]]>Måske der er gang i en sektor rotation.?

]]>https://dev.proinvestor.com/forum/post/10156146https://dev.proinvestor.com/forum/post/10156146Thu, 31 Aug 2017 15:18:08 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:16:52 GMT]]>Men NBI stiger også meget.

]]>https://dev.proinvestor.com/forum/post/10156139https://dev.proinvestor.com/forum/post/10156139Thu, 31 Aug 2017 15:16:52 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:12:28 GMT]]>Ja , Sgen oppe med over 6 %

]]>https://dev.proinvestor.com/forum/post/10156135https://dev.proinvestor.com/forum/post/10156135Thu, 31 Aug 2017 15:12:28 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 15:09:40 GMT]]>Godt nok er det en plusdag, men check lige SGEN. Jeg kan ikke se, at der er kommet noget nyt omkring dem

]]>https://dev.proinvestor.com/forum/post/10156134https://dev.proinvestor.com/forum/post/10156134Thu, 31 Aug 2017 15:09:40 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 14:31:23 GMT]]>is highly encouraging and it does not change any of our data conclusions from the previous flash note distributed."

]]>https://dev.proinvestor.com/forum/post/10156137https://dev.proinvestor.com/forum/post/10156137Thu, 31 Aug 2017 14:31:23 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 14:31:17 GMT]]>ORR was reported, but not defined as an ORR as the study had not been finalised. This compares to the 37% mentioned in the ESMO abstract released today. We were aware that the ESMO abstract submission deadline was 10 May 2017, ie before Genmab’s headline release, but it remains somewhat confusing that the abstract describes response rates at time of release of abstract versus at time of abstract submission. In any case, the ORR of 32% (and 37% at an earlier stage described in the abstract),

]]>https://dev.proinvestor.com/forum/post/10156133https://dev.proinvestor.com/forum/post/10156133Thu, 31 Aug 2017 14:31:17 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 14:30:52 GMT]]>Har lige opdaget dette Nordea Flash fra i formiddags "Equity Flash Comment - Flash Comment , Genmab A/S

We have been made aware that the abstract data for Tisotumab Vedotin may not be the most updated cut-off. This, despite the abstract describing that responses have increased from 6 to 7 from the abstract submission to the release of the data in the abstract. We have discussed it with Genmab and the company notes that the most updated data is from the company release on 16 June, where a 32%

]]>https://dev.proinvestor.com/forum/post/10156132https://dev.proinvestor.com/forum/post/10156132Thu, 31 Aug 2017 14:30:52 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 14:25:16 GMT]]>Nok rigtigt. Men da de søgte på Castor og Pollux skrev de at de også søgte PR.

]]>https://dev.proinvestor.com/forum/post/10156129https://dev.proinvestor.com/forum/post/10156129Thu, 31 Aug 2017 14:25:16 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 14:13:30 GMT]]>Men mon ikke ansøgningen er på vej med kurer. Den slags kan vi ikke betro post & telegrafen

]]>https://dev.proinvestor.com/forum/post/10156130https://dev.proinvestor.com/forum/post/10156130Thu, 31 Aug 2017 14:13:30 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 14:12:24 GMT]]>Ansøgning om btd får vi vel næppe noget at vide om. Os almindelige dødelige kommer vel først in the know, når btd tildeles. Hvis btd altså tildeles....

]]>https://dev.proinvestor.com/forum/post/10156136https://dev.proinvestor.com/forum/post/10156136Thu, 31 Aug 2017 14:12:24 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 14:11:40 GMT]]>Skete der noget mærkeligt i lukkeminutter?? Syntes det ser ud som om den var nede og kysse 1430 !!!!! ?

]]>https://dev.proinvestor.com/forum/post/10156128https://dev.proinvestor.com/forum/post/10156128Thu, 31 Aug 2017 14:11:40 GMT<![CDATA[Reply to Genmab — August 2017 on Thu, 31 Aug 2017 13:07:29 GMT]]>1458

]]>https://dev.proinvestor.com/forum/post/10156126https://dev.proinvestor.com/forum/post/10156126Thu, 31 Aug 2017 13:07:29 GMT